fda glp-1 compounding enforcement news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our September 8, 2025: FDA launches

Discover the clinical reasons behind rebound weight gain and how ongoing treatment maintains results

Aprende qu son los medicamentos GLP-1, cmo funcionan en el cuerpo y por qu se discuten comnmente en conversaciones sobre peso y salud metablica.

But some see much less benefit, and researchers are trying to figure out why.

You asked

In fact, the similar pathological mechanisms shared by PD and T2DM have inspired several studies on the therapeutic potential of T2DM drugs against PD, among which glucagon-like peptide-1 receptor (GLP-1R) agonists are promising candidates

Learn why semaglutide can cause nerve pain (allodynia) and how to manage skin tenderness during weight loss.